Newsfeeds Archive - Spark Newswire

1 minute read

Pharvaris N.V. EPS €(0.74) Vs €(1.16) YoY; Cash And Cash Equivalents Were ~€391 Million As Of December 31, 2023

April 10, 4:14 PM

Fourth Quarter and Full Year 2023 Financial ResultsLiquidity Position. Cash and cash equivalents were approximately €391 million as of December 31, 2023, compared to approximately €162 million for December 31,

PHVS

1 minute read

FDA Clears Pharvaris’ Trial For Investigational Drug For Swollen Blood Vessels, Stock Jumps

By Vandana Singh

January 22, 1:28 PM

Pharvaris receives FDA approval to advance deucrictibant for hereditary angioedema prophylaxis, lifting clinical hold. Learn about the latest developments in HAE treatment.

PHVS

2 minute read

Analyst Ratings

Analyst Expectations for Pharvaris’s Future

By Benzinga Insights

December 7, 10:00 AM

Within the last quarter, Pharvaris (NASDAQ:PHVS) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

PHVS

3 minute read

Gold Moves Higher; Campbell Soup Earnings Top Expectations

By Lisa Levin

December 6, 3:45 PM

U.S. stocks traded mixed toward the end of trading on Wednesday. The Dow traded up 0.05% to 36,143.40 while the NASDAQ fell 0.06% to 14,221.51. The S&P 500 also fell, dropping, 0.05% to 4,564.73.

CPB

4 minute read

Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

December 6, 3:43 PM

Shares of AeroVironment, Inc. (NASDAQ: AVAV) moved lower during Wednesday’s session following second-quarter results.

AAOI

1 minute read

Turnaround For Pharvaris Since FDA Clinical Hold – Data Shows Its Oral Hereditary Angioedema Treatment Cuts Attacks

By Vandana Singh

December 6, 1:46 PM

Pharvaris NV (NASDAQ: PHVS) released topline data from the CHAPTER-1 Phase 2 study meeting its primary endpoint, with deucrictibant demonstrating statistically significant and clinically meaningful results as an oral preventative treatment for people living with

PHVS

3 minute read

Crude Oil Down 4%; Pharvaris Shares Spike Higher

By Lisa Levin

December 6, 1:29 PM

U.S. stocks traded mostly flat midway through trading, with the S&P 500 turning lower on Wednesday. The Dow traded up 0.01% to 36,126.75 while the NASDAQ rose 0.03% to 14,233.77. The S&P 500 also fell, dropping, 0.05% to 4,565.09.

IPA

2 minute read

THOR Industries Reports Upbeat Earnings, Joins Dave & Buster’s Entertainment, Campbell Soup And Other Big Stocks Moving Higher On Wednesday

By Lisa Levin

December 6, 11:48 AM

U.S. stocks traded higher, with the Dow Jones index gaining more than 50 points on Wednesday.

AAOI

3 minute read

US Stocks Higher; Private Payrolls Rise By 103,000 In November

By Lisa Levin

December 6, 10:42 AM

U.S. stocks traded higher this morning, following the release of economic reports on Wednesday. Following the market opening Wednesday, the Dow traded up 0.21% to 36,200.86 while the NASDAQ rose 0.28% to 14,270.30. The S&P 500 also rose, gaining, 0.32% to 4,581.88.

IPA

2 minute read

Pharvaris Presents Deucrictibant Clinical Data And Real-World HAE Treatment Satisfaction Data At ACAAI 2023 Annual Scientific Meeting

By Benzinga Newsdesk

November 9, 12:08 PM

Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the presentation of two ePosters at

PHVS